Trial · NCT01126255
Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus
NCT01126255, Phase 2, Terminated, Insel Gruppe AG, University Hospital Bern
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus. Trials, record NCT01126255. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01126255
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus
- NCT number
- NCT01126255
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 37 participants, actual
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Conditions
- Vulvar Lichen Sclerosus
- Interventions
- Clobetasol propionate 0.05%, Progesterone 8%
- First posted
- 2010-05-19
- Last updated
- 2022-04-01
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Score of the characteristics of Lichen sclerosus based on vulvar efflorescences | at 12 weeks | The severity of the Lichen sclerosus will be assessed by a metric score, which is based on 6 items (abrasion, hyperkeratosis, rhagades, synechia, sclerosis, atrophy of labia/clitoris) consisting of three levels (0=no signs, 1=few signs, 2=pronounced signs). |
| Secondary | Patient-reported symptoms | at baseline | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Quality of life | at baseline | The patient will report quality of life on the SF12 questionnaire. |
| Secondary | Adverse events | at baseline | The tolerability of the topical treatment will be assessed by all adverse events occuring at the site of application. |
| Secondary | Patient-reported symptoms | at 6 weeks | The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 12 weeks | The patient will report the following symptoms on a scale from 0 to 10: pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 18 weeks | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Patient-reported symptoms | at 24 weeks | The patient will report the following symptoms on a scale from 0 to 10 pruritus, burning or pain, sore. |
| Secondary | Quality of life | at 12 weeks | The patient will report quality of life on the SF12 questionnaire. |
| Secondary | Quality of life | at 24 weeks | The patient will report quality of life on the SF12 questionnaire. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35290878 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01126255
GET https://conductscience.org/api/trials/v1/NCT01126255/registered